The treatment of hyperlipidemia in patients infected with HIV is discussed. Hyperlipidemia is common in HIV-infected patients receiving antiretroviral therapy, especially protease inhibitors and ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized MUIR study of investigational plozasiran (formerly ...

Research led by Baylor College of Medicine has shown that a new therapy significantly reduces triglyceride levels in individuals with mixed hyperlipidemia – elevations of triglycerides and cholesterol ...

In a recent study published in The New England Journal of Medicine, researchers evaluate the efficacy of plazosiran treatment on fasting triglyceride levels in adult patients with mixed hyperlipidemia ...

I am looking for information on the use of inositol hexaniacinate ("no-flush niacin") in the treatment of hyperlipidemia. Most of the information I have been able to find is anecdotal. I understand ...

In a breakthrough for cardiovascular medicine, researchers have harnessed artificial intelligence to discover unexpected lipid-lowering effects in existing FDA-approved drugs. The study, published in ...

Korea Pharma is set to develop an orally disintegrating tablet of ‘Rosujet,’ the top outpatient prescription item for hyperlipidemia treatment. On the 7th, Korea Pharma announced that it has signed a ...

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "US Hyperlipidemia Market and Competitive Landscape Highlights - 2016" drug pipelines to their offering. US ...

Machine learning models, particularly LightGBM, effectively predict hyperlipidemia in PLWH on HAART for six months, with high accuracy and area under curve values. The study's limitations include ...

Explore practical implications of new research in nephrotic syndrome, from renal biopsy and genetic testing to managing ...